A Translational Neuroscience Approach to the Prevention & Treatment of Substance Use Disorder
A 3-part series hosted by The Program for Translational Research on Adversity and Neurodevelopment (P-TRAN) at Pennsylvania State University.
Despite notable advances in identifying the biological pathways that confer risk for or resilience against substance use disorders (SUD), the effective transfer and application of this scientific knowledge from the neuroscience and related biomedical fields to SUD prevention science is sorely lacking. Advances in the integration of neuroscience and prevention (i.e., so-called “neuro-prevention”) are needed and have the potential to inform the delineation of which types of intervention work best for whom, why, and under what circumstances. The Program for Translational Research on Adversity and Neurodevelopment (P-TRAN) symposium series convened investigators whose work is or could be aligned with a translational neuroscience approach to developing more effective interventions to disrupt pathways to SUD’s. The series brought substance use investigators and trainees from biomedical/neuroscience and prevention science together with invested stakeholders to advance a transdisciplinary translational approach to address the gaps in SUD prevention. This series was funded by a NIDA R13 conference grant and led by Drs. Emma Jane Rose and Diana Fishbein at Pennsylvania State University.
The series began with a discussion of relevant findings from neuroscience and biomedical fields that provide a blueprint for development of adaptive intervention strategies to more specifically target underlying generators of the phenomenon we seek to prevent. Methodological advances are presented that enable optimization of programs and clinical trials to compare personalized intervention models to one-size-fits-all” programs. And third, effective approaches to translate the science to end-users (e.g., program developers, implementation specialists, evaluators, agency and organizational audiences, and policymakers) are placed in the context of applied and policy-relevant format to more maximally benefit program recipients.
*There are no conflicts of interest to report.
6 Continuing Education Credits
Session 1.1: Dr. Susan Andersen (Harvard) – Using mechanisms of substance dependence to identifying risk and intervention: Insight from preclinical studies
Session 1.2: Dr. Scott Bunce (Penn State University) – Translational neuroimaging to estimate relapse vulnerability: Using what we know about the brain in addiction to learn what we do not
Session 1 Quiz
Session 2.1: Dr. Marc Potenza (Yale University School of Medicine) – Neuroimaging and biomarkers in addiction treatment
Session 2.2: Dr. Rajita Sinha (Yale University School of Medicine) – Substance abuse relapse related to adversity, trauma, and altered stress neural and biobehavioral responses
Session 2 Quiz
Session 3.1: Dr. Velma McBride Murry (Vanderbilt) – Translating research into preventive interventions: Enhancing protective processes in African American families
Session 3.2: Dr. Leslie Leve (U. Oregon) - Intervention outcomes for women with prior correctional system involvement: Early adversity and biological indicators of health
Session 3 Quiz
Describe the importance of targeting substance use disorder prevention approaches to specific aspects of behavioral, affective, cognitive and neural functioning in order to better target underlying mechanisms of addiction and identify individuals at high risk for developing substance use disorder.
Describe the importance of targeting substance use disorder treatment approaches to specific aspects of behavioral, affective, cognitive and neural functioning in order to better target underlying mechanisms of addiction and identify individuals at high risk for poor treatment outcomes including relapse.
Explain how patterns of neural connectivity and neural response are associated with risk for substance use disorder and behavioral addictions.
Explain how changes to the brain are associated with response to preventive interventions and substance use disorder treatment.
Identify at least two promising approaches to preventing substance use disorder among high-risk individuals that are supported by neuroscience findings.
Identify at least two promising approaches to treating substance use disorder that are supported by neuroscience findings.
Director of Translational Prevention Research, FPG Child Development Institute, University of North Carolina; Research Faculty, Human Development and Family Studies and Affiliate of the Prevention Research Center, Pennsylvania State University; President and Co-Director of the National Prevention Science Coalition to Improve Lives
Former Director of the Laboratory of Developmental Neuropharmacology at McLean Hospital; Associate Professor of Psychiatry, Harvard Medical School
Associate Professor of Psychiatry, Pennsylvania State University
Professor of Psychiatry, Child Study Center and of Neuroscience; Director, Center of Excellence in Gambling Research; Director, Yale Program for Research on Impulsivity and Impulse Control Disorders; Director, Women and Addictive Disorders, Women's Health Research at Yale
Foundations Fund Professor of Psychiatry and Professor in the Child Study Center and of Neuroscience; Director, Yale Interdisciplinary Stress Center; Chief, Psychology Section in Psychiatry; Co-director of Education, Yale Center for Clinical Investigation
Lois Audrey Betts Chair, Education and Human Development; University Professor, Department of Human and Organizational Development; University Professor, Health Policy, Vanderbilt University
Lorry Lokey Chair, Professor; Associate Director, Prevention Science Institute; Associate Vice President for Research College of Education, Counseling Psychology, Family and Human Services, Prevention Science, University of Oregon
Select the pricing option that fits you best.
Regular price (non-member)
Early Career (within 5 yrs)
NPSC Paying Member/Affiliate
Add your email to the mailing list to get the latest updates.